Hyloris Pharmaceuticals (LTS:0AB6) Interest Expense: €-0.07 Mil (TTM As of Dec. 2025)


LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
21 GF Score
Price €4.50
GF Value €9.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Interest Expense?

Hyloris Pharmaceuticals LTS:0AB6 -0.66% 21 Interest Expense is €-0.07 Mil as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 21/100 and a GF Value™ of €9.57 (Possible Value Trap). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hyloris Pharmaceuticals's interest expense for the six months ended in Dec. 2025 was € -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.07 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hyloris Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was € -4.19 Mil. Hyloris Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was € -0.02 Mil. Hyloris Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hyloris Pharmaceuticals  (LTS:0AB6) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hyloris Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was €-0.02 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-4.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €1.25 Mil.

Hyloris Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Hyloris Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Hyloris Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Interest Expense Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.56 -0.22 -0.05 -0.08 -0.07

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.04 -0.04 -0.05 -0.02
LTS:0AB6
21GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.07 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Interest Expense of €-0.07 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Interest Expense too high?
Hyloris Pharmaceuticals' current Interest Expense is €-0.07 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 21/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Interest Expense compare to VRTX and REGN?
Hyloris Pharmaceuticals' Interest Expense of €-0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Interest Expense is €-0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.57, compared to a current price of €4.50 — trading 53% below its estimated fair value. The current Interest Expense is €-0.07 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Interest Expense is €-0.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.50 is trading 53% below its estimated GF Value™ of €9.57. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

  • Interest Expense: €-0.07 Mil
  • GF Value™: €9.57 vs. price of €4.50 (53% below fair value)
  • GF Score™: 21/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
21GF Score

Get the complete analysis for LTS:0AB6

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.50
Price
€9.57
GF Value